Perfluorocarbon MRI Contrast Agent for Bladder Wall Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging modalities struggle to effectively image diseased lesions of the bladder wall due to challenges in controlling the dynamic concentration of contrast agents and achieving sufficient image contrast between the bladder wall and lumen.
Innovation Solution
A contrast agent composition comprising at least 10 mM of a gadolinium chelate in an emulsion with at least 10% w/v of a perfluorocarbon is administered directly into the bladder, enhancing signal in the bladder wall while simultaneously masking signals in the bladder lumen through signal decay.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If intravenous gadolinium chelate is administered, then image resolution for certain organs is improved, but image contrast of bladder wall lesions is confounded by transient arrival and excreted gadolinium chelate in urine
Solution Approach 1:
The patent divides the administration route into two separate pathways: intravenous injection for systemic organ imaging and intravesical injection for bladder wall imaging. This segmentation allows each route to be optimized for its specific purpose, avoiding the conflict where IV gadolinium chelate improves general organ resolution but confounds bladder wall lesion contrast due to urinary excretion.
Solution Approach 2:
The patent introduces an intermediary substance (perfluorocarbon emulsion) that acts as a signal-decaying agent in the bladder lumen. This intermediary masks the confounding signal from excreted gadolinium chelate in urine, allowing the bladder wall lesions to be visualized with improved contrast despite the presence of excreted contrast agent.
2Illumination intensity
If high concentration of contrast agent is administered to enhance lesion signal, then signal in bladder wall is improved, but signal decay in lumen is insufficient and artifacts increase
Solution Approach 1:
The patent changes the concentration parameter of the contrast agent formulation by using high concentration (at least 10 mM) of gadolinium chelate in the intravesical emulsion. This high concentration provides sufficient signal decay in the lumen to mask artifacts while simultaneously providing adequate signal enhancement in the bladder wall lesions when the emulsion contacts the tissue.
Solution Approach 2:
The patent creates a composite contrast agent system combining gadolinium chelate (for signal enhancement and decay) with perfluorocarbon emulsion (for stable lumen signal masking). This composite formulation allows the two contrasting functions—enhancing lesion signal and suppressing lumen signal—to work together without conflict, reducing MRI artifacts while maintaining high contrast.
3Ease of operation
If intravesical route is used for localized administration, then selective brightening of lesioned bladder wall is achieved, but control over dynamic concentration at disease site remains challenging
Solution Approach 1:
The patent employs the self-service principle where the intravesically administered emulsion naturally distributes and contacts the bladder wall lesions, allowing the lesions to be brightened selectively based on their inherent contrast properties. The system uses the body's own physiological processes (urine production, bladder filling) to maintain the contrast agent at the disease site, reducing the need for external control mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves image contrast and allows for better visualization of bladder wall lesions, overcoming the limitations of perfusion-dependent contrast enhancement and reducing MRI artifacts.
Implementation Method 1
obtain a magnetic resonance imaging image of the patient's bladder containing the emulsion composition
Implementation Method 2
masking signals in the bladder lumen through signal decay
Implementation Method 3
enhancing signal in the bladder wall while simultaneously decreasing or masking signals in the bladder lumen
Data Source
AI summary
Provided herein is a contrast agent composition comprising a contrast agent, such as a gadolinium chelate contrast agent, and a perfluorocarbon. Provided herein also is a method of imaging a patient's bladder or other organs containing a cavity, using MRI using a contrast agent composition comprising a contrast agent, such as a gadolinium chelate contrast agent, and a perfluorocarbon.